| Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-choice stent compared to the paclitaxel-eluting TAXUS Stent. | |
| | |
MedLine Citation:
|
PMID: 20358534 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Previously the polymer-free sirolimus-eluting YUKON-Choice stent (A) has demonstrated noninferiority compared to the polymer-based paclitaxel-eluting TAXUS stent (B). To test for long-term equivalency in unselected real-world coronary lesions of various complexities, we retrospectively compared both stents. METHODS: A total of 410 patients with symptomatic coronary artery disease (CAD) were treated with stent A (n = 205) or stent B (n = 205). Baseline clinical characteristics, lesion location, and length and the number of stents implanted per lesion were equally distributed. Clinical follow-up with assessment of major adverse cardiac events (MACE) and noncardiac deaths was obtained at 9 and 12 months. RESULTS: Nominal stent diameter and nominal length of the stented segment were without differences between the groups. The incidence of MACE after 12 months was significantly higher in group A (35.1%) compared to group B (16.6%, P = .001). This was mainly due to increased rates of target-lesion revascularizations in group A (13.7%) vs group B (4.4%, P = .005). No significant differences in target-vessel revascularizations and non-target-vessel revascularizations were observed. In group B, 1 stent thrombosis was documented (0.5%) vs none in group A (P > .05); in each group 1 myocardial infarction (MI), but no cardiac deaths occurred; 3 noncardiac deaths in group A (1.5%) vs 7 in group B (3.4%) were observed (P = .3). CONCLUSIONS: In contrast to our previous findings indicating no differences in MACE between patients treated with the polymer-free sirolimus-eluting YUKON-Choice stent and the polymer-based paclitaxel-eluting TAXUS stent at 6 months, we herewith show that 12 months after percutaneous coronary intervention (PCI) of real-world coronary lesions the YUKON stent appears to be inferior due to increased target-lesion revascularization (TLR) rates as a consequence of delayed restenosis. |
| | |
Authors:
|
Johannes Ruef; Hans St?rger; Franz Schwarz; J?rgen Haase |
Related Documents
:
|
23302004 - Orthotopic bladder replacement in women: focus on functional results of a retrospective... 23220244 - Half-century follow-up after ureterosigmoidostomy in early childhood. 3162044 - Clinical experience of percutaneous transluminal coronary angioplasty--technique and re... 14699214 - Immediate and medium-term outcomes following the treatment of very long (> or =50 mm) c... 15493034 - Fungicidal effect of diode laser irradiation in patients with denture stomatitis. 23105124 - Comparison of a powered bone marrow biopsy device with a manual system: results of a pr... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Clinical cardiology Volume: 33 ISSN: 1932-8737 ISO Abbreviation: Clin Cardiol Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-04-15 Completed Date: 2010-05-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7903272 Medline TA: Clin Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: E33-8 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Wiley Periodicals, Inc. |
Affiliation:
|
Red Cross Hospital Cardiology Center, Frankfurt, Germany. j.ruef@kardiocentrum.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Coronary Angiography Coronary Disease / drug therapy* Coronary Restenosis / epidemiology*, radiography Drug-Eluting Stents* Female Graft Occlusion, Vascular / epidemiology, radiography Humans Immunosuppressive Agents / administration & dosage* Male Paclitaxel / administration & dosage* Prosthesis Design Retrospective Studies Sirolimus / administration & dosage* Treatment Outcome Tubulin Modulators / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents; 0/Tubulin Modulators; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Technetium-99m-sestamibi Redistribution after Exercise Stress Test Identified by a Novel Cardiac Gam...
Next Document: Evaluation of the Surface ECG in Detecting Isthmus Conduction Block after Ablation of Typical Atrial...